皮下注射硼替佐米治疗多发性骨髓瘤的效果观察  

Effect of subcutaneous injection of bortezomib in the treatment of multiple myeloma

作　　者：容建创[1] RONG Jianchuang(Dept.of Pharmacy,the 1st People's Hospital of Foshan,Foshan 528000,China)

机构地区：[1]佛山市第一人民医院药学部,广东佛山528000

出　　处：《华夏医学》2019年第5期94-97,共4页Acta Medicinae Sinica

摘　　要：目的:探讨多发性骨髓瘤患者应用硼替佐米皮下注射治疗效果。方法:选取本院诊治的多发骨髓瘤70例患者资料,按随机数表分两组,对照组予硼替佐米常规注射,研究组予硼替佐米改良注射方案,分析两组疗效、不良反应及疼痛度情况。结果:治疗后,研究组CR(完全缓解)为42.86%、PR(部分缓解)为40.00%,对照组依次为37.14%,40.00%,两组差异无统计学意义(P>0.05);研究组出现红斑、肿胀等不良反应(20.48%)比对照组(42.38%)少,差异有统计学意义(P<0.05);且研究组疼痛VAS(3.08±1.12)分低于对照组(4.86±1.69)分,差异有统计学意义(P<0.05)。结论:多发性骨髓瘤患者应用硼替佐米皮下注射可降低不良反应发生,改善患者疼痛度,具有一定临床应用价值。Objective:To analyze the effect of subcutaneous injection of bortezomib in patients with multiple myeloma.Methods:Data of 70 patients with multiple myeloma diagnosed and treated in our hospital were selected,who were randomized into two groups.The control group was given bortezomib for routine injection,while the study group adopted bortezomib modified injection protocol.Then the efficacy,adverse reactions and pain degree of two groups were analyzed.Results:After treatment,CR(complete remission)of the study group was 42.86%,PR(partial remission)was 40.00%,and the control group was 37.14%and 40.00%,respectively.There were no statistical significance(P>0.05);the adverse reactions such as erythema and swelling were 20.48%less than that of the control group(42.38%),which was of statistical difference(P<0.05);and the pain VAS was(3.08±1.12)in the study group,lower than that in the control group(4.86±1.69),which was statistically significant(P<0.05).Conclusion:The clinical efficacy of subcutaneous injection of bortezomib in patients with multiple myeloma is significant,and the improved subcutaneous injection can reduce the incidence of adverse reactions and the pain degree of patients,which has certain clinical application values.

关 键 词：多发性骨髓瘤 硼替佐米 皮下注射 不良反应 疼痛度 

分 类 号：R733.3[医药卫生—肿瘤]